Janney Montgomery Scott LLC Purchases 11,806 Shares of Sanofi (NASDAQ:SNY)

Janney Montgomery Scott LLC grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 3.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 339,437 shares of the company's stock after acquiring an additional 11,806 shares during the period. Janney Montgomery Scott LLC's holdings in Sanofi were worth $18,825,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of SNY. Lee Danner & Bass Inc. bought a new position in Sanofi in the fourth quarter valued at about $31,000. Bessemer Group Inc. boosted its stake in shares of Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares during the last quarter. UMB Bank n.a. grew its position in shares of Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after buying an additional 264 shares during the period. Whipplewood Advisors LLC bought a new stake in shares of Sanofi during the fourth quarter worth approximately $76,000. Finally, Kestra Investment Management LLC acquired a new position in Sanofi in the fourth quarter valued at approximately $84,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SNY has been the subject of several recent research reports. The Goldman Sachs Group started coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday, June 2nd. BNP Paribas assumed coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Trading Down 1.2%

Shares of Sanofi stock traded down $0.60 during trading hours on Thursday, hitting $47.62. The company's stock had a trading volume of 2,782,958 shares, compared to its average volume of 2,377,740. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The company has a market capitalization of $116.79 billion, a PE ratio of 17.01, a price-to-earnings-growth ratio of 0.97 and a beta of 0.50. The stock has a 50 day moving average of $51.35 and a 200 day moving average of $52.01.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. During the same period in the prior year, the business earned $1.78 EPS. Sanofi's revenue for the quarter was down 11.0% compared to the same quarter last year. Analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were issued a dividend of $2.0369 per share. This represents a dividend yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. Sanofi's dividend payout ratio (DPR) is presently 56.79%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.